Oxford Global Conferences are proud to present the 5th Annual Biosimilars & Biobetters Congress co-located with the 11th Annual Proteins & Antibodies Congress and the 5th Annual Peptides Congress, taking place on the 16-17 April 2018 in London.
Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions
Over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
Two-day interactive conference addressing the following topics:
Market Access Strategies, Opportunities, Clinical Development and Commercial Challenges
Developing Biosimilars and Biobetters – Manufacturing and Bio-analytics
Free Pre-Congress Live Webinars
Biosimilars: Everyday Practice, Manufacturing Pre-Clinical Trials
Hosted by Katalin Egyed, International Oncology and Onco-biotechnology Business Unit Manager, EGIS Pharmaceuticals and Rafał Derlacz, Senior Project Manager, Polpharma.
Wednesday 7th February 2018 | 10am GMT
Register today for free: http://bit.ly/2xNJGbG
Biosimilars: The Cancer Patient Perspective
Hosted by Lydia Makaroff, Director, European Cancer Patient Coalition
Tuesday 13th February 2018 | 10am GMT
Register today for free: http://bit.ly/2j1vAAf
Can’t make the dates? Still register and a copy of the webinar recording will be sent to you.
For further information, prices & discounts please contact firstname.lastname@example.org
View Agenda here:
We encourage all who are interested in the clinical practice and research on infections in immunocompromised host to attend the 20th ICHS Symposium in Athens, Greece June 17-19, 2018. Many symposia, plenary sessions, poster sessions will provide the attendee with opportunities to meet with outstanding leaders and clinical experts in the broad field of infectious diseases and immune-deficiencies while covering such diverse topics as new diagnostics, infections in transplant recipients, invasive fungal infections and resistance, treatment of multi-resistant bacteria, infectious complications in immunocompromised children, life-threatening infections and intensive care in neutropenic cancer patients ,antiviral and antifungal immune responses in compromised hosts, prophylaxis and treatment of viral infections in immunocompromised hosts, and others.